Showing 3741-3750 of 6978 results for "".
- Tara L. Azzano Appointed Executive Director of ASDShttps://practicaldermatology.com/news/tara-l-azzano-appointed-executive-director-asds/2462658/The American Society for Dermatologic Surgery (ASDS), the largest organization in the U.S. dedicated solely to dermatologic surgeons, announced the appointment of Tara L. Azzano as Executive Director, according to a news release. Ms. Azzano brings with her over two decades of experience
- New Data Show Efficacy of Topical 0.1% Stabilized Bioactive Retinol for Photoaginghttps://practicaldermatology.com/news/analysis-data-shows-efficacy-topical-01-stabilized-bioactive-retinol-photoaging/2462643/A recent integrated analysis published in the Journal of Drugs in Dermatology showed the efficacy and tolerability of topical 0.1% stabilized bioactive retinol in countering the signs of photoaging. "Advances in formulation science have allowed the production of stabilized bioact
- Study: Pembrolizumab Shows Efficacy in Japanese Patients with Advanced Melanomahttps://practicaldermatology.com/news/study-pembrolizumab-shows-efficacy-japanese-patients-advanced-melanoma/2462539/A recent analysis of the phase 1b KEYNOTE-041 trial indicated effectiveness and tolerability of pembrolizumab in Japanese patients with advanced melanoma. Researchers conducted the study over a 12-month period. The study evaluated pembrolizumab's long-term efficacy and safety in individua
- Galderma Prices IPO; Will Start Trading on the Swiss Stock Exchange Todayhttps://practicaldermatology.com/news/galderma-prices-ipo-will-start-trading-on-the-swiss-stock-exchange-today/2462444/Dermatology leader Galderma Group announced the pricing of its initial public offering at CHF 53 ($59) per share in Switzerland. The shares will be listed and start trading under the ticker symbol “GALD” on the SIX Swiss Exchange, on March 22, 2024. At the recent A
- Study Highlights Orofacial Anomalies in Kindler Epidermolysis Bullosahttps://practicaldermatology.com/news/orofacial-anomalies-in-kindler-epidermolysis-bullosa/2462441/A new study in JAMA Dermatology suggests that hypoplastic pitted amelogenesis imperfecta is a feature of Kindler epidermolysis bullosa (KEB). "Kindler epidermolysis bullosa is a genetic skin-blistering disease associated with recessive inherited pathogenic varia
- Shaperon Enrolls First Patient in Phase 2 Clinical Trial for Atopic Dermatitis Therapy 'Nugel'https://practicaldermatology.com/news/shaperon-enrolls-first-patient-in-phase-2-clinical-trial-for-atopic-dermatitis-therapy-nugel/2462439/Shaperon announced the enrollment of the first patient in the phase 2 clinical trial for atopic dermatitis treatment candidate Nugel. The trial will evaluate the efficacy of Nugel in improving the Eczema Area Severity Index (EASI) across a cohort of 210 patients with mild to moderate atop
- New Analysis Provides Evidence-based Recommendations for Vitiligo in Pediatric Patientshttps://practicaldermatology.com/news/evidence-based-recommendations-for-treating-vitiligo-in-pediatric-patients-insights-from-comprehensive-review/2462436/A new consensus statement published in JAMA Dermatology provided evidence-based expert recommendations for the treatment of vitiligo in pediatric, adolescent, and young adult patients. The authors undertook a rigorous examination of existing literature and expert consensus, aimi
- Almirall Partners with Eloxx Pharmaceuticals to Target Rare Dermatological Diseaseshttps://practicaldermatology.com/news/almirall-partners-with-eloxx-pharmaceuticals-to-target-rare-dermatological-diseases/2462435/Almirall and Eloxx Pharmaceuticals, Inc., announced today that they have partnered to exclusively license ZKN-013, in what they call a "potential game-changer" for the treatment of rare dermatological disorders. The agreement grants Almirall global rights to develop
- New Data on Long-Term Efficacy of Nemolizumab in Prurigo Nodularis and Its Durability in ADhttps://practicaldermatology.com/news/new-data-on-long-term-efficacy-of-nemolizumab-in-prurigo-nodularis-and-its-durability-in-ad-1/2462433/Galderma announced new data demonstrating nemolizumab’s long-term and increasing efficacy on skin lesions and other symptoms in prurigo nodularis through to week 52 in the OLYMPIA LTE study.[1] Additionally, data from the ARCADIA 1 and 2 trials in atopic dermatitis indicate that the majority of p
- INTEGUMENT-PED: Roflumilast Cream 0.05% Effective at Improving AD in Childrenhttps://practicaldermatology.com/news/integument-ped-roflumilast-cream-005-effective-at-improving-ad-in-children/2462429/New data from a pivotal phase 3 trial indicates roflumilast cream 0.05% is associated with significantly improved atopic dermatitis (AD) in children 2 to 5 years of age with mild-to-moderate AD. Researchers for the Interventional Trial Evaluating Roflumilast Cream for the Treatment of Ato